La Jolla, CALIFORNIA5 Active Studies

Kidney Cancer Clinical Trials in La Jolla, CALIFORNIA

Find 5 actively recruiting kidney cancer clinical trials in La Jolla, CALIFORNIA. Connect with local research sites and explore new treatment options.

5
Active Trials
4
Sponsors
1,675
Enrolling

Recruiting Kidney Cancer Studies in La Jolla

RecruitingLa Jolla, CALIFORNIANCT07000149

A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC

This is a Phase Ib/III, randomized, multicenter, global study evaluating the efficacy and safety of volrustomig in combination with casdatifan for the first-line (1L) treatment of participants with ad...

1,116 participants
AstraZeneca
View Study Details
RecruitingLa Jolla, CALIFORNIANCT05327686

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherap...

240 participants
NRG Oncology
View Study Details
RecruitingLa Jolla, CALIFORNIANCT04071223

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

This phase II trial studies whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the bone. Radioactive dru...

134 participants
National Cancer Institute (NCI)
View Study Details
RecruitingLa Jolla, CALIFORNIANCT05928806

Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial

This study is a randomized, open label, multicenter Phase II trial to evaluate the efficacy and safety of botensilimab (a novel Fc enhanced Tree depleting anti-CTLA4) and balstilimab (a novel anti-PD1...

120 participants
Michael B. Atkins, MD
View Study Details
RecruitingLa Jolla, CALIFORNIANCT04981509

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

This phase II trial studies the effects of combination therapy with bevacizumab, erlotinib, and atezolizumab in treating patients with hereditary leiomyomatosis and kidney cancer that may have spread ...

65 participants
National Cancer Institute (NCI)
View Study Details

About Kidney Cancer Clinical Trials in La Jolla

Kidney cancer, most commonly renal cell carcinoma, develops in the lining of the kidney tubules. It accounts for about 3-5% of all adult cancers. Treatment includes surgery, targeted therapy, immunotherapy, and radiation.

There are currently 5 kidney cancer clinical trials recruiting participants in La Jolla, CALIFORNIA. These studies are seeking a combined 1,675 participants. Research is being sponsored by AstraZeneca, NRG Oncology, National Cancer Institute (NCI) and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Kidney Cancer Clinical Trials in La Jolla — FAQ

Are there kidney cancer clinical trials in La Jolla?

Yes, there are 5 kidney cancer clinical trials currently recruiting in La Jolla, CALIFORNIA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in La Jolla?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the La Jolla research site will contact you about next steps.

Are clinical trials in La Jolla free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many La Jolla studies also compensate for your time and travel.

What kidney cancer treatments are being tested?

The 5 active trials in La Jolla are testing new therapies including novel drugs, biologics, and treatment approaches for kidney cancer.

Data updated March 2, 2026 from ClinicalTrials.gov